Specific fields

pelyon-expertise-assistance-conseil

Epidemiological studies

Epidemiological data summaries

Implementation of descriptive and analytical epidemiological studies according to ENCePP guidelines

undraw_charts_jj6t

Pharmacoepidemiology

Surveys of practice patterns

Correct drug use evaluation

Comparative effectiveness research

pelyon-expertise-evaluations

Assessment

Health programs and actions,

Health policies

pelyon-expertise-etude-economique

Economic studies

Cost of illness studies

Medico-economic studies of treatments or diagnostic methods

Evaluation of healthcare consumption

pelyon-expertise-assistance-conseil

Methodological assistance and advice

pelyon-expertise-image-outils
Our tools

Our studies are carried out using several databases from the Health Data Hub

Health insurance reimbursement database

DCIR: database covering over 90% of the population with health insurance in France, or around 65 million patients

EGB: sample of 1/97th of the DCIR database

PMSI: database that includes all hospital stays in French public and private healthcare facilities (data generated by the ATIH and linked to the SNIIRAM)

Probabilistic linkage with private data or data from registers.

Confidentiality and independence

Studies carried out by PELyon are conducted in compliance with articles L. 1460-1 et seq. and R. 1461-1 et seq. of the French Public Health Code.

In this respect, PELyon has made a commitment to the Commission nationale de l’informatique et des libertés [French data protection authority] to comply with the frame of reference establishing the confidentiality, expertise and independence criteria for research laboratories and research departments as set out by the decree of 17 July 2017 (NOR: SSAE1720859A). This compliance undertaking demonstrates the commitment made by PELyon, and its employees, to comply with a number of confidentiality, security and independence measures in the context of its processing of personal data

PELyon also complies with the security frame of reference applicable to the National Health Data System resulting from the decree of 22 March, 2017 (NOR: AFSE1705146A).
01

Study on adherence to asthma treatments

02

Initiation of anti-osteoporotic treatment and healthcare consumption

03

Early adherence to anti-glaucoma therapy

04

Assessment of the safety of long-acting beta-2-agonists in routine asthma care

05

Management and costs of rheumatoid arthritis

06

Frequency of comorbidities in COPD and impact on mortality

07

Management and healthcare consumption of patients with an NSCLC cancer or metastatic melanoma

08

Epidemiology and management of bone metastases